MRK250110C107000
- 0.04
- 0.000.00%
Merck & Co Newsroom
Cramer on Merck & Co. (MRK): Trading Like a Value Trap Despite Strong Fundamentals
Atropos Health Collaborates With Merck for Rapid Evidence Generation to Accelerate Innovation for Life-Saving Treatments
Two major pieces of news have come from Trump! Within a few hours after the inauguration ceremony, Trump will accomplish these significant tasks.
According to a report from Bloomberg on Thursday (January 9), the recently elected president of the USA, Donald Trump, plans to issue a series of executive orders within a few hours after his inauguration ceremony on January 20, addressing issues such as immigration, Energy, federal employees, and regulatory reforms. This is part of his comprehensive effort to swiftly implement his policy agenda after taking office.
IO Biotech Completes Enrollment in Phase 2 Trial of Cancer Vaccine to Treat Resectable Melanoma
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
Express News | The Merck PD-1 inhibitor, Keytruda, has been approved in China for the indication of locally advanced or metastatic urothelial carcinoma treatment.
Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110
Astra, Merck Drugs Set to Shake Up Liver Cancer Treatment
Bernstein Sticks to Their Hold Rating for Merck & Company (MRK)
Merck Rival Summit Draws New Buy From Truist on Deal Prospects
Merck, Johnson & Johnson Share Losses Lead Dow's 180-Point Fall
The HPV vaccine for males has been approved in the country, with Merck being the first to enter the market!
Will the male market be a lifeline?
Major banks rating | Truist: The biopharmaceutical Industry needs more mergers and acquisitions to recover, lowering Merck's Target Price to $110.
Glonghui, January 8 | Truist Securities states that the biopharmaceutical Industry in 2024 is disappointing in terms of mergers and acquisitions; the Industry requires larger/more merger transactions to recover. Truist downgraded Merck's rating from "Buy" to "Hold," with the Target Price lowered from $130 to $110. (Glonghui)
Global Equities Roundup: Market Talk
Merck's Near-Term Growth Path Uncertain -- Market Talk
Merck Gets Expanded Approval From China for Its HPV Vaccine in Males
Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday
UBS Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $120